CA2055435A1 - Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii - Google Patents

Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii

Info

Publication number
CA2055435A1
CA2055435A1 CA002055435A CA2055435A CA2055435A1 CA 2055435 A1 CA2055435 A1 CA 2055435A1 CA 002055435 A CA002055435 A CA 002055435A CA 2055435 A CA2055435 A CA 2055435A CA 2055435 A1 CA2055435 A1 CA 2055435A1
Authority
CA
Canada
Prior art keywords
rna
retroviral vector
cell
stably transformed
foreign
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002055435A
Other languages
English (en)
Inventor
Eli Gilboa
Bruce Sullenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2055435A1 publication Critical patent/CA2055435A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
CA002055435A 1989-05-10 1990-05-10 Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii Abandoned CA2055435A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US354,171 1982-03-03
US35417189A 1989-05-10 1989-05-10
PCT/US1990/002656 WO1990013641A1 (fr) 1989-05-10 1990-05-10 Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii

Publications (1)

Publication Number Publication Date
CA2055435A1 true CA2055435A1 (fr) 1990-11-11

Family

ID=23392147

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002055435A Abandoned CA2055435A1 (fr) 1989-05-10 1990-05-10 Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii

Country Status (4)

Country Link
EP (1) EP0471796A4 (fr)
JP (1) JPH04505261A (fr)
CA (1) CA2055435A1 (fr)
WO (1) WO1990013641A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
US6251675B1 (en) 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
ES2335720T3 (es) 1991-01-21 2010-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
DE4225094A1 (de) * 1992-04-28 1993-11-04 Frank Andreas Harald Meyer Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
WO1993024133A1 (fr) * 1992-05-27 1993-12-09 City Of Hope MOLECULES CHIMERIQUES DE RIBOZYMES D'ARNt?LYS¿
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
ATE312188T1 (de) * 1993-01-22 2005-12-15 Univ Research Corp Lokalisierung von therapeutischen mitteln
WO1994026877A1 (fr) * 1993-05-17 1994-11-24 The Regents Of The University Of California Therapie genique ribozymique contre l'infection par le vih et contre le sida
JPH10500281A (ja) * 1994-02-14 1998-01-13 ザ マクファーレーン バーネット センター フォー メディカル リサーチ リミテッド 非病原性ｈｉｖ−１種
US6015661A (en) * 1994-02-14 2000-01-18 The Macfarlane Burnet Centre For Medical Research Limited Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
AU2133695A (en) * 1994-04-06 1995-10-30 Sadna Joshi-Sukhwal Inhibition of hiv-1 multiplication in mammalian cells
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
KR100510234B1 (ko) 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
DE69636124T2 (de) 1995-09-29 2006-12-21 Indiana University Research And Technology Corp., Bloomington Verfahren zum verbesserten virusvermittelten dns-transfer unter verwendung von molekülen mit virus- und zellbindenden domänen
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US5955644A (en) * 1996-08-08 1999-09-21 M.D. Anderson Cancer Center Ku deficient cells and non-human transgenic animals
US6057489A (en) * 1996-09-12 2000-05-02 M.D. Anderson Cancer Center MmRad51-deficient cells and transgenic mice
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
EP3112468A1 (fr) 1998-05-15 2017-01-04 Genentech, Inc. Polypeptides allogéniques il-17 et utilisations thérapeutiques
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
EP1865061A3 (fr) 1998-05-15 2007-12-19 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
WO2000011174A1 (fr) 1998-08-21 2000-03-02 Immunex Corporation Adn humain il-1 epsilon et polypeptides
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4931310B2 (ja) 1999-10-20 2012-05-16 ジェネンテック， インコーポレイテッド ヘルパーｔ細胞性疾患の治療のためのｔ細胞分化の調節
JP2004522404A (ja) 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
EP2163625B1 (fr) 1999-12-23 2014-05-21 Genentech, Inc. Polypeptides homologues IL-17 et IL-17R et utilisations thérapeutiques
EP1246917B1 (fr) 2000-01-13 2009-03-04 Genentech, Inc. Polypeptides humains stra6
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
EP1757618A3 (fr) 2000-03-22 2007-05-23 Curagen Corporation Proteines associées a l'angiogenese et acides nucleiques codant pour les dites proteines
EP1944317A3 (fr) 2000-09-01 2008-09-17 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK2000545T3 (da) 2001-06-20 2011-11-28 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
CA2460120A1 (fr) 2001-09-18 2003-03-27 Genentech, Inc. Compositions et procedes pour le diagnostic et le traitement des tumeurs
JP2005525095A (ja) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
JP2005518212A (ja) 2002-02-25 2005-06-23 ジェネンテック・インコーポレーテッド 新規な１型サイトカインレセプターｇｌｍ−ｒ
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20050004914A (ko) 2002-06-07 2005-01-12 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
PL1641822T3 (pl) 2003-07-08 2013-10-31 Genentech Inc Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
CA2747871C (fr) 2003-11-17 2018-04-10 Genentech, Inc. Compositions et methodes de traitement d'une tumeur d'origine hematopoietique
RU2007137489A (ru) 2005-03-10 2009-04-20 Дженентек, Инк. (Us) Способы и композиции для модуляции целостности сосудов
CA2610709A1 (fr) 2005-06-06 2006-12-14 Genentech, Inc. Nouvelles disruptions geniques, nouvelles compositions et nouveaux procedes s'y rapportant
WO2007021423A2 (fr) 2005-08-15 2007-02-22 Genentech, Inc. Disruptions et compositions geniques et procedes associes
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
JP2009516514A (ja) 2005-11-21 2009-04-23 ジェネンテック・インコーポレーテッド 新規遺伝子破壊、それらに関する組成物および方法
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
EP2614839A3 (fr) 2006-04-05 2015-01-28 Genentech, Inc. Méthode d'utilisation du BOC/CDO pour moduler l'émission des signaux du hedgehog
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
WO2009097006A2 (fr) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 et hco27 et exemples connexes
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
JP5697027B2 (ja) 2008-02-15 2015-04-08 タフツ ユニバーシティー マウス網膜上への細胞膜傷害複合体（ｍａｃ）生成のヒト化モデル、並びに、黄斑変性の処置のための組成物とキットと方法
CA2772715C (fr) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened et ses methodes d'utilisation
EP2488643A4 (fr) 2009-10-15 2013-07-03 Hoffmann La Roche Facteurs de croissance chimériques des fibroblastes avec spécificité de récepteur modifiée
WO2011050194A1 (fr) 2009-10-22 2011-04-28 Genentech, Inc. Procédés et compositions pour moduler l'activation d'hepsine d'une protéine de stimulation de macrophage
TWI507524B (zh) 2009-11-30 2015-11-11 Genentech Inc 診斷及治療腫瘤之組合物及方法
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2012021891A2 (fr) 2010-08-13 2012-02-16 Tufts University Compositions, kits et méthodes de traitement de pathologies associées au complément
JP5974012B2 (ja) 2010-10-05 2016-08-23 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
WO2015116902A1 (fr) 2014-01-31 2015-08-06 Genentech, Inc. Récepteurs couplés aux protéines g dans la signalisation hedgehog
AU2015214264B2 (en) 2014-02-04 2018-12-20 Curis, Inc. Mutant Smoothened and methods of using the same
ES2872537T3 (es) 2014-08-28 2021-11-02 Univ Tufts Composiciones, métodos y kits para el tratamiento de trastornos relacionados con el complemento
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
CN109071625A (zh) 2016-02-04 2018-12-21 柯瑞斯公司 平滑化突变体和其使用方法
US20210052743A1 (en) 2018-02-12 2021-02-25 Trustees Of Tufts College Cd59 for inhibiting inflammasome activation
WO2023089564A1 (fr) 2021-11-19 2023-05-25 Janssen Biotech, Inc. Méthode de traitement d'une atrophie géographique avec un vecteur de thérapie génique exprimant cd59 soluble

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
DK0387775T3 (da) * 1989-03-16 1996-11-04 Boehringer Ingelheim Int Genetisk enhed til inhibering af funktionen af RNA

Also Published As

Publication number Publication date
JPH04505261A (ja) 1992-09-17
WO1990013641A1 (fr) 1990-11-15
EP0471796A1 (fr) 1992-02-26
EP0471796A4 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
CA2055435A1 (fr) Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii
McBride et al. Position dependence of functional hairpins important for human immunodeficiency virus type 1 RNA encapsidation in vivo
Lee et al. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain
Dropulić et al. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression
Amendt et al. Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1
US5650309A (en) Viral vectors
Das et al. A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication
Sullenger et al. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication
Tabernero et al. The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function
JP2004532616A (ja) 二本鎖ｒｎａ仲介遺伝子抑制
WO1993011230A1 (fr) Cellule souche modifiee de mammifere bloquant la replication virale
JP2746480B2 (ja) 遺伝子発現に影響を与える多重標的応答因子をもつベクター
To et al. Inhibition of retroviral replication by anti-sense RNA
DE69534864T2 (de) Ribozyme gegen eine HIV Tat Sequenz
US20040253604A1 (en) RNA-mediated gene modulation
Gdovin et al. Molecular mechanisms of visna virus Tat: identification of the targets for transcriptional activation and evidence for a post-transcriptional effect
Berberich et al. Mutations in the regions of the Rous sarcoma virus 3'splice sites: implications for regulation of alternative splicing
WO1994016060A1 (fr) Mutants de vih destines a la suppression des infections par vih
JPS62501398A (ja) トリ赤芽球症ウイルスゲノムを含有するクロ−ニング又は発現ベクタ−及びそれらのベクタ−によりトランスフェクションされた細胞
Taylor et al. Interferon treatment inhibits the replication of simian immunodeficiency virus at an early stage: evidence for a block between attachment and reverse transcription
AU703964B2 (en) Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
WO1995031477A1 (fr) Vecteurs a sequences tar multiples du vih-1 inhibant l'expression genique du vih-1
DE69333216T2 (de) Vektor, enthält ein bei ARN-Polymerase-III transcriptes Virus-Gen
Gelinas et al. Long-Term Expression of the Human ß-Globin Gene After Retroviral Transfer into Pluripotent Hematopoietic Stem Cells of the Mouse
US5753490A (en) Recombinant HIV and modified packaging cells and method for treating acquired immune deficiency syndrome

Legal Events

Date Code Title Description
FZDE Dead